NEW YORK, Nov. 7 – Myriad Genetics said Wednesday its fiscal first quarter revenues increased 22 percent to $13.2 million, compared with $10.8 million a year ago, boosted by strong sales of the company’s diagnostic products.

Myriad of Salt Lake City said that product revenues alone increased 81 percent in the quarter to $5.5 million. The company manufactures the BracAnalysis product for breast and ovarian cancer and the Colaris product for colon and uterine cancer.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers have sequenced the northern white rhinoceros to gauge whether it could be brought back from the edge of extinction, the New York Times reports.

Bavaria expands its forensic genetic analyses to include DNA phenotyping, raising discrimination concerns.

Tufts University researchers found a role for miRNA in transmitting stress between generations, the Economist reports.

In Science this week: gut microbiome influences liver cancer growth, spread; and more.